Microbiology, Antimicrobial Resistance and Outcomes of Neonatal Sepsis in China

Launched by CHILDREN'S HOSPITAL OF FUDAN UNIVERSITY · Oct 20, 2021

Keywords

ClinConnect Summary

This clinical trial is focused on understanding neonatal sepsis, a serious infection that affects newborns, and is a major cause of illness and death in China. The study will collect information from infants in neonatal intensive care units (NICUs) across China who have been diagnosed with this condition. Researchers will look closely at the germs causing the infections, how these germs resist treatment with antibiotics, and the health outcomes for these babies. This information will help improve care for future patients.

To participate in the trial, infants must be admitted to a participating NICU between January 1, 2022, and December 31, 2023, and must have a diagnosis of culture-proven sepsis, which means their infection has been confirmed by lab tests. There are no specific exclusions for this study, so if your baby meets the criteria, they may be eligible. Parents can expect that their child's information will be collected and monitored carefully, helping to better understand and combat this serious condition in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Admitted to CHNN NICUs from 2022.1.1 to 2023.12.31
• • Diagnosed with culture-proven sepsis
• Exclusion Criteria:
• • None